NCT06830395View on ClinicalTrials.gov

Study of CM313 in Subject With IgA Nephropathy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

August 31, 2028

Conditions
IgA Nephropathy
Interventions
BIOLOGICAL

CM313

CM313(SC) injection

DRUG

Placebo

Matched placebo

Trial Locations (1)

Unknown

Peking University First Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Keymed Biosciences Co.Ltd

INDUSTRY

NCT06830395 - Study of CM313 in Subject With IgA Nephropathy | Biotech Hunter | Biotech Hunter